A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

類似資料

• A Post-hoc Comparison of Paliperidone Palmitate to Oral Risperidone During Initiation of Long-acting Risperidone Injection in Patients with Acute Schizophrenia
  著者:: Gopal, Srihari, 等
  出版事項: (2011)
• Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
  著者:: Samtani, Mahesh N, 等
  出版事項: (2013)
• Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia
  著者:: Shimizu, Hiroko, 等
  出版事項: (2019)
• Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
  著者:: Ravenstijn, Paulien, 等
  出版事項: (2016)
• PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
  著者:: Mathews, Maju, 等
  出版事項: (2016)